Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12339214 | 1.00 | ACHE (0.44) | ACHESMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL12107720 | 0.91 | ACHE (0.52) | ACHESMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL20353134 | 0.91 | ACHE (0.52) | ACHESMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL12892798 | 0.90 | ACHE (0.46) | ACHESMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL15223682 | 0.88 | ACHE (0.52) | ACHESMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL12339213 | 0.84 | MEN1 (0.43) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21135341 | 0.84 | MEN1 (0.46) | ACHESMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL19771216 | 0.84 | ACHE (0.50) | ACHE | |
| SCHEMBL19240711 | 0.84 | ACHE (0.50) | ACHE | |
| SCHEMBL22452414 | 0.83 | ACHE (0.41) | ACHESMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835556-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | NEKTAR THERAPEUTICS (US) | 2012-09-06 | — | — | US | disclosed |
| US-8227555-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120123065-A1 | Hydrolytically Stable Maleimide-Terminated Polymers | NEKTAR THERAPEUTICS (US) | 2012-05-17 | — | — | US | disclosed |
| US-8106131-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS (US) | 2012-01-31 | — | — | US | disclosed |
| US-20090012241-A1 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-01-08 | — | — | US | disclosed |
| US-7432331-B2 | Hydrolytically stable maleimide-terminated polymers | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226022-A1 | HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS | PADI6, MPI, VIM | ACHE 792/4885SMN1; SMN2 1150/4885LMNA 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.